secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0000950170-24-037624
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel reports Q4 2023 net loss $11.1M; cash $35.4M; Phase 3 prostate data on track for Q4 2024
--------------------------------------------------------------------------------

- Net loss Q4 2023 $11.1M vs $5.1M Q4 2022; full year net loss $37.9M vs $18.8M.
- Cash and equivalents $35.4M at Dec 31, 2023 ($70.1M end 2022); expects runway into Q4 2024.
- R&D expenses $7.3M Q4 2023 ($5.0M Q4 2022) and $24.5M full year ($20.8M 2022).
- FDA Fast Track Designations: CAN-2409 for NSCLC and pancreatic cancer, CAN-3110 for recurrent HGG.
- Anticipated milestones: Phase 2 NSCLC data Q2 2024; Phase 3 prostate topline data Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024037624/0000950170-24-037624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024037624/cadl-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-037624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer